Online and face-to-face programmes to suit your CPD needs, apply now for September 2018
Page URL: https://www.bionews.org.uk/page_90832

Discredited cloning technology patented in Australia

6 October 2008
Appeared in BioNews 478

The Australian Patent Office, IP Australia, are expected to grant a patent to internationally disgraced South Korean Scientist Hwang Woo-Suk for his human cloning technology which he fraudulently claimed led to false scientific achievements in 2005. Hwang is one of 18 researchers named on the patent application lodged in eleven countries by Hwang's team six months after his work was discredited, in June 2006. Most countries rejected the application, but patents are pending in the US, Canada, India and China.

David Johnson, acting commissioner of patents for IP Australia explained, 'There is no statutory basis to refuse to grant a patent on the basis that the scientific data in a patent application is a misrepresentation or fraudulently obtained.'

The Australian legal test is whether the technology is new, involves an inventive step, fully described and adequately defined. A patent is not granted on the basis of utility - whether the technology performs as it claims - and Australia is one of the few countries that do not require authors to sign a statement of truth in relation to their data. Only the Courts have the power to revoke a patent.

In 2004, Hwang's team announced the creation of the world's first cloned human embryonic stem cell-line (ES cell) and, in 2005, reported in the journal Science the derivation of a further 11 cell-lines, genetically matched to specific patients, a breakthrough which if genuine could pave the way for regenerative medicine, whereby healthy tissue and organs are re-grown from a patient's own cells. Both achievements were later discovered to have been faked.

Hwang publicly apologised but always maintained that the technique was valid and he had been deceived by junior researchers. Now banned from performing human cloning research, Hwang now focuses his research on animal cloning, where he has announced several major breakthroughs, all of which have been publically verified by experts.

David Earp, chief patent lawyer at the biopharmaceutical company 'Geron', believes that Australia should reject the patent because they already own the patent for the Dolly cloning technique and all its applications including embryonic stem cells. Although it is nonetheless expected to be granted, Johnson stresses, 'IP Australia is not endorsing the research that underpins the patent'. The impact of the patent is unclear. Some stem cell biologists speculate that Australia may want to patent the technology because new techniques are far more expensive. In September, officials licensed the first Australian group to conduct similar human therapeutic cloning research at Sydney IVF.

SOURCES & REFERENCES
Clone row scientist to get patent
The Press Association |  22 September 2008
Disgraced scientist seeks clone patent
The Sydney Morning Herald |  24 September 2008
Hwang work granted patent
Nature |  1 October 2008
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
27 August 2013 - by Dr Anna Cauldwell 
Canadian dentist Michael Zuk, who spent almost £20,000 on one of John Lennon's rotten molars at an auction in 2011, now plans to sequence Lennon's DNA in the hope of cloning him....
17 October 2011 - by Jessica Ware 
A US doctor accused of implanting stem cells into chronically ill patients pleaded not guilty at a court hearing on Thursday 13 October. Dr Ralph Conti, of Henderson, Nevada, has been accused of transplanting stem cells harvested from placental tissue into patients, at the direction of Alfred Sapse, who was falsely claiming to be a doctor....
26 October 2009 - by Antony Blackburn-Starza 
A South Korean court has convicted disgraced stem cell scientist, Hwang Woo-Suk, of embezzling funds and purchasing human eggs for research, after a trial lasting over three years. Hwang was given a two-year sentence suspended for three years by the Seoul Central District Court last week...
1 September 2009 - by Nishat Hyder 
Disgraced scientist, Hwang Woo-suk found last Monday that he faces a possible four year jail term for alleged embezzlement, and the violation of Korean bioethics law....
4 August 2008 - by Antony Blackburn-Starza 
The South Korean Health Ministry has rejected a licence application to carry out stem cell research made by the company owned by disgraced stem cell scientist, Hwang Woo-Suk, citing 'ethical problems'. The Suam Biotech Research Foundation had requested approval last December to resume its research on human...
27 May 2008 - by Antony Blackburn-Starza 
US company BioArts International has teamed up with disgraced South Korean scientist Hwang Woo-Suk to offer dog cloning services to the public. Five dog owners will be given the opportunity to have their pet cloned in a worldwide auction on 18 June this year, where bidding will...
6 August 2007 - by Antony Blackburn-Starza 
The disgraced South Korean stem cell scientist, Woo Suk Hwang, whose spectacular fall from grace dominated the newspaper headlines early last year, has been credited with 'accidentally' creating the world's fisrt stem cells produced from an unfertilised human egg. An international collaboration of scientists last week published...
18 May 2006 - by Dr Kirsty Horsey 
South Korean stem cell scientist Woo Suk Hwang has been formally prosecuted on charges of fraud and embezzlement - if convicted he could spend up to 10 years in prison. He was charged with accepting two billion won (about $2.1 million) in private donations based on his...
3 February 2006 - by BioNews 
South Korea's national bioethics committee has produced a report on the 'serious ethical problems' with the donated human eggs used in the recently discredited stem cell research carried out by Woo Suk Hwang and his team. Korea's National Bioethics Board (KNBB) says that the scientists, based at Seoul National University...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.